Stocksigma LogoStocksigma Logo

Emcure Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

■ Revenue: 28,205 (+24.3% YoY | +9.3% QoQ) ■ EBITDA: 5,878 (+23.6% YoY | +10.4% QoQ) ■ EBITDA Margin (%): 20.8 (-11 bps YoY | +21 bps QoQ) ■ PAT: 3,256

Emcure Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

Emcure Pharmaceuticals Ltd · Outcome · 03 Nov 2026, 7:11 pm

Emcure Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 28,205 (+24.3% YoY | +9.3% QoQ) ■ EBITDA: 5,878 (+23.6% YoY | +10.4% QoQ) ■ EBITDA Margin (%): 20.8 (-11 bps YoY | +21 bps QoQ) ■ PAT: 3,256 (+33.7% YoY | +10.7% QoQ) ■ EPS (INR): 17.1 (+33.4% YoY | +10.6% QoQ)

Original exchange filing (PDF)

More announcements from Emcure Pharmaceuticals Ltd

All Emcure Pharmaceuticals Ltd announcements